Patent intelligence · EP
EP 4541380
STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN
STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN
Patent details — EP 4541380
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Apr 23, 2025
- Expiration
- Apr 18, 2045
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 47/ 12 A I, A61K 47/ 22 A I
Quick answer
EP 4541380 (STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN) is held by ADVANCED ACCELERATOR APPLICATIONS S A [FR]. Status: granted. Granted Apr 23, 2025. Expires Apr 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 47/ 12 A I, A61K 47/ 22 A I, A61K 51/ 08 A I, A61K 51/ 12 A I
More from ADVANCED ACCELERATOR APPLICATIONS S A [FR]
Related pharmaceutical patents in our USPTO index.
-
CA 3235923
PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES
granted -
CA 3240096
POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON
granted -
CA 3234495
POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES
granted -
CA 3215723
PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE
granted -
CA 3202908
ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE
granted -
US 2022072166
METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
granted -
WO 2022043557
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
granted
Frequently asked questions
What is US patent 4541380?
EP 4541380 (STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN) is held by ADVANCED ACCELERATOR APPLICATIONS S A [FR]. Status: granted. Granted Apr 23, 2025. Expires Apr 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4541380?
ADVANCED ACCELERATOR APPLICATIONS S A [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 4541380 expire?
Our index shows an expiration date of Apr 18, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.